Conformis, Inc. to Release Third Quarter 2021 Financial Results on November 3, 2021

Rhea-AI Summary

Conformis, Inc. (NASDAQ: CFMS) will announce its third-quarter financial results for the period ending September 30, 2021, on November 3, 2021. The results will be available after market close, around 4:00 p.m. ET. Following the release, CEO Mark Augusti and CFO Bob Howe will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can access the call via webcast or telephone. The company specializes in personalized joint replacement solutions, utilizing their iFit® technology platform.

Positive

• Conformis utilizes proprietary technology for personalized joint replacements.
• The upcoming earnings report may present growth opportunities for investors.

Negative

• None.

BILLERICA, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the market closes on November 3, 2021 at approximately 4:00 p.m. Eastern Time.

Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, November 3, 2021, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update.

The webcast will be live at: https://edge.media-server.com/mmc/p/wvne4ujy

To attend by telephone, please use the information below for dial-in access.  

• When prompted on dial-in, please utilize conference ID: 1757322.
• Participant conference numbers: (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).
• Please dial in at least 10 minutes before the call to ensure timely participation.
  

Please visit the Investor Relations website at ir.conformis.com on November 3, 2021 to view the earnings release prior to the webcast and conference call.

The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit^® Image-to-Implant^® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy.   Conformis also offers Identity Imprint^™, a new line of total knee replacement products that utilizes a proprietary algorithm to select the implant size that most closely meets the geometric and anatomic requirements of the patient’s knee. Conformis’ sterile, just-in-time, Surgery-in-Box^™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.

Contact

Investor Contact:
Investor Relations
ir@conformis.com
(781) 374-5598

FAQ

When will Conformis release its Q3 2021 financial results?

Conformis will release its Q3 2021 financial results on November 3, 2021, after market close.

What time is the Conformis conference call scheduled for?

The conference call for discussing financial results is scheduled for November 3, 2021, at 4:30 p.m. ET.

How can I access the Conformis conference call?

You can access the Conformis conference call via webcast or by dialing in with the provided conference ID.

What is the focus of Conformis as a company?

Conformis focuses on developing and manufacturing personalized joint replacement implants that fit individual patient anatomies.